NZ243201A - Sustained release tablets containing indapamide. - Google Patents

Description

24 32 0 1 . ... - . . VS-<o- <\\ j * r 'r r • 1 * * ■ ' * • • • ■ i Compit^w Specification CISKK^lfra W . . J J. a. •.Vf^ .......

Pviblicotion Date: .....?. f£P. .,. P.O. Journal, Nc: ..... ArOT) NEW ZEALAND PATENTS ACT, 1953 No.: Date: COMPLETE SPECIFICATION 4 P£#hiwtiCr MATRIX TABLET/PRMITTINe THE SUSTAINED RELEASE OF INDAPAMIDE AFTER ORAL ADMINISTRATION We, ADIR ET COMPAGNIE, a French body corporate, of 1 rue Carle Hebert, F-92415 Courbevoie, Cedex, France, hereby declare the invention for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- - 1 -(followed by page la) - lg- 24 32 ( The subject of the present invention is a matrix tablet permitting the sustained release of indapamide, ensuring uniform and constant blood levels after absorption of the galenic form by the oral route.

Indapamide, a compound of formula (I): HNCO "SQ2m2 (I) is a non-thiazidic sulphamide derivative with an antihypertensive property at the usual doses administered to humans.

Indapamide has been, up until now, administered by the oral route at a dose of 2.5.mg per day by means of an immediate-release form.

Now, an immediate-release form can lead, in certain patients, to considerable blood peaks. A 15 sustained-release form allows these blood peaks to be avoided and a uniform blood concentration to be obtained in humans. This makes it possible to reduce the undesirable effects, which can arise as a result of the "peak effect", accompanied by hydroelectrolytic-type and 20 metabolic-type disorders linked to variations in the plasma levels of the active principle.

A sustained-release form of indapamide therefore ensures a better therapeutic index in the treatment of essential arterial hypertension.

To do this, a sustained release over time, in a precisely controlled manner, must be ensured. The speed of release must be reproducible and correlated with the blood concentrations observed after administration.

Among the mechanisms which may be employed to control the diffusion of a soluble active principle, the diffusion of the active principle through a gel formed after the swelling of a hydrophilic polymer brought into 5 contact with dissolving liquid (in vitro) or gastrointestinal fluid (in vivo) may be cited as a principal one.

Many polymers have been described as capable of forming this gel. The principal ones are the derivatives 10 of cellulose, in particular the cellulose ethers such as hydroxypropyl cellulose, hydroxymethyl cellulose, methyl cellulose or methyl hydroxypropyl cellulose, and among the different commercial grades of these ethers are those showing fairly high viscosities. It should be noted that 15 the systems described do not theoretically allow a zero order in the kinetic release equation to be reached.

The manufacturing processes commonly employed for the manufacture of such matrix tablets are either direct compression, after mixing the different excipients and 20 active principle(s), or wet granulation.

The matrix tablet described in the present invention combines, in a novel manner, two polymers of different chemical families, which allows a precisely controlled release of the active principle. Furthermore, 25 this combination is perfectly suited to the physicochemical properties of indapamide.

This controlled release is linear for more than eight hours and is such that 50 per cent of the total quantity of indapamide is released over a period of 30 between 5 and 14 hours. Moreover, the matrix tablet according to the invention allows a sustained release of indapamide resulting in blood levels in humans of between 20 and 80 ng/ml, 24 hours at the most after administration of the tablet. The unit dosage can thus 35 vary according to the age and the weight of the patient or the nature and the severity of the ailment. Generally, it ranges between 1 and 2.5 mg for a daily course of treatment.

The first polymer is a high-viscosity methyl hydroxypropyl cellulose, the second is a polyvidone. The combination of these two polymers allows release kinetics in vitro which are linear (of zero order) for more than 8 hours. The percentage of polymer derived from cellulose is between 30 and 50 % of the total mass of the tablet, while that derived from polyvidone is between 2 and 10 % of the total mass of the tablet.

These two polymers are used separately in the tablet in order to ensure, in a reproducible manner, control of the release of the active principle. A novel manufacturing process has itself been developed so that each polymer used in the formulation can play its part in the most effective manner possible with the advantages of the two processes of wet granulation and direct compression.

A wet granulation is carried out with the polyvidone, in order to create, around the active principle, a hydrophilic environment favorable for its good dissolution, and also so as to obtain the most uniform unit dosage possible, the indapamide content of the finished tablet being approximately 1 percent. Lactose, a hydrophilic diluent, is employed to this end.

After this granulation stage, a direct compression mixture is made and then tableted.

The examples which follow illustrate the invention but do not limit it in any way. The preparation of the sustained-release tablets is carried out according to the manufacturing process which follows: Stage A: Mixing of indapamide, the polyvidone and the lactose, then wetting of this mixture by means of an aqueous/alcoholic solution. The wet mass prepared is then granulated, dried and then graded, so as to obtain a granulate whose physical characteristics allow good filling of the dies of a fast tableting machine. 24320 1 Mixing of the granulate obtained in stage A with methyl hydroxypropyl cellulose.

Lubrication of the mixture obtained in stage B with colloidal silica and magnesium stearate.

Compression of the lubricated mixture obtained in stage C in a rotary tableting machine, so as to obtain tablets having a hardness, measured by diametrical crushing, of approximately 60 to 75 N.

EXAMPLE 1: A sustained-release tablet (SR 1) is prepared by employing the formula given in Table 1, following the operating procedure of stages A to D.

Table 1: Unit formula of the SR 1 tablet » Stage B: Stage C: Stage D: Compound Quantity (mg) Indapamide 2.5 Lactose 114.9 Polyvidone 6.2 Methyl hydroxypropyl cellulose 59.0 Magnesium stearate 2.0 Colloidal silica 0.4 \l'HAItl993i The dissolution profile in vitro of this form (SR 1) is shown in Figure 1 (appended). The blood concentrations of indapamide were measured in six patients after administration of the SR 1 tablet or of an immediate-release tablet (IR). The mean curve is given in Figure 2 (appended).

EXAMPLE 2: A sustained-release tablet (SR 2) is prepared by employing the formula given in Table 2, following the operating procedure described in stages A to D.

Table 2 : Unit formula of the SR 2 tablet Compound Quantity (mg) Indapamide 2.5 Lactose 114.9 Polyvidone 6.2 Methyl hydroxypropyl cellulose 74.0 Magnesium stearate 2.0 Colloidal silica 0.4 The dissolution profile in vitro of this form is shown in Figure 3 (appended).

The blood concentrations of indapamide were measured in six patients after administration of the SR 2 tablet or of an immediate-release form (IR). The mean curve is given in Figure 4 (appended).

The comparison between the formulae described in 20 Examples 1 and 2, differing only in the quantity of methyl hydroxypropyl cellulose, shows that it is easy to control the kinetics of dissolution in vitro of indapamide. The relationship with the blood kinetics measured in vivo is very good. The two blood kinetics are found 25 to be significantly different.

EXAMPLES 3 TO 5; Three sustained-release tablets (SR 3, SR 4 and SR 5) are prepared by employing the formulae given in Table 3, following the operating process described in 30 stages A to D. 24 3 2 0 1 Table 3 : Unit formula of the SR 3, SR 4 and SR 5 tablets Tablet LP 3 LP 4 LP 5 Quantity (rag) (mg) (mg) Indapamide 2.0 2.0 2.0 Lactose 115.4 113.0 113.0 Polyvidone 6.2 8.6 8.6 Methyl hydroxypropyl cellulose 74.0 74.0 59.0 Magnesium stearate 2.0 2.0 2.0 Colloidal silica 0.4 0.4 0.4 The dissolution profiles in vitro of these three forms are shown in Figure 5 (appended). They show that, 20 by moderating the concentration of each polymer in the formula, it is possible to modulate the release of the active principle.

Claims (8)

1. O L T *.3;jL h o £.;- 7 -;what/aa/e claim is;1. Matrix tablet for the sustained release of indapamide r wherein this sustained release is controlled by the use of a polymer derived from cellulose and of a polymer derived from polyvidone, wherein the percentages of the derivatives of cellulose and of polyvidone are respectively between 30 and 50 % w/w and between 2 and 10 % w/w of the total mass of the tablet.;
2. 2. Matrix tablet of indapamide as claimed in claim 1, wherein the percentages of the derivatives of cellulose and of polyvidone allow a sustained release of indapamide which is linear for at least eight hours.;15
3. 3. Matrix tablet of indapamide as claimed in claim;1, wherein the percentages of the derivatives of cellulose and of polyvidone allow the release of 50 per cent of the total quantity of indapamide over a period of between 5 and 14 hours.;20
4. 4. Matrix tablet of indapamide as claimed in claim;1, wherein the percentages of the derivatives of cellulose and of polyvidone allow a sustained release of indapamide leading to blood levels in humans of between 20 and 80 ng/ml, 24 hours at the most after;25 administration of the tablet by the oral route.;
5. 5. Process for the preparation of a matrix tablet of indapamide as claimed in claim 1, wherein a wet granulation technique and a direct compression technique are both employed, according to the manufacturing process which follows:;Stage A: Mixing of indapamide, the polyvidone and the lactose, then wetting of this mixture by means of an aqueous/alcoholic solution, then granulation, drying and then grading, so as to obtain a granulate whose physical characteristics allow good filling of the dies of a fast tableting machine,;/< A;j*2 1 DEC 1993 2 4 3 2 0 - 8 - Stage B: Mixing of the granulate obtained in stage A with methyl hydroxypropyl cellulose, Stage C: Lubrication of the mixture obtained in stage B with colloidal silica and magnesium stearate, Stage D: Compression of the lubricated mixture obtained in stage C in a rotary tableting machine, so as to obtain tablets having a hardness, measured by diametrical crushing, of substantially 60 to 75 N.
6. 6. Matrix tablet of indapamide as claimed in any one of claims 1 to 5, suitable for use in the treatment of essential arterial hypertension.
7. 7. Matrix tablet for the sustained release of indapamide as defined in claim 1 substantially as herein described with reference to the examples.
8. 8. Process for the preparation of a matrix tablet of indapamide as defined in claim 5 substantially as herein described with reference to the examples. A hi ft ET CO MPS) CIV I/f By the authorised agents A J PARK & SON